Finally, the abundance of IDH1/2 mutations in gliomas and cholangiocarcinomas, but lack of TET2 mutations, are likely a reflection of TET enzymes functioning in tissue specific patterns—TET1, for example, has very recently been shown to be an oncogenic driver in IDH‐wt cholangiocarcinoma.135. The gene discussed is TET2; the disease is cholangiocarcinoma.